Plus Therapeutics (NASDAQ:PSTV) Given “Hold” Rating at D. Boral Capital

D. Boral Capital reissued their hold rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note released on Tuesday,Benzinga reports.

A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. Lake Street Capital initiated coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $1.00 price target (down from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.60.

Plus Therapeutics Stock Down 24.2%

Shares of PSTV stock opened at $0.16 on Tuesday. The company has a market capitalization of $27.89 million, a PE ratio of -0.13 and a beta of 0.79. Plus Therapeutics has a 12-month low of $0.16 and a 12-month high of $1.22. The firm has a 50 day moving average price of $0.26 and a two-hundred day moving average price of $0.46.

Plus Therapeutics’s stock is going to reverse split on Thursday, April 2nd. The 1-25 reverse split was announced on Tuesday, March 31st. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, April 1st.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Plus Therapeutics in the 2nd quarter valued at approximately $41,000. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics during the third quarter worth $46,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics during the third quarter worth $100,000. XTX Topco Ltd bought a new position in shares of Plus Therapeutics in the 4th quarter valued at $127,000. Finally, State Street Corp boosted its holdings in shares of Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after acquiring an additional 127,000 shares in the last quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.